MARAGANORE JOHN 4

What Happened

• John Maraganore, a director of Hemab Therapeutics Holdings, reported a grant and multiple derivative conversions. The filing shows a 107,338-share award (warrant) granted on 2026-01-29 (reported as derivative, $0.00) and conversion entries on 2026-05-04 converting derivative securities into common stock (two acquisitions of 17,974 shares each and two reported dispositions of 817 shares each). All transactions are reported at $0.00 consideration. Net reported change from these entries is an increase of 141,652 common shares (per the Form 4).

Key Details

• Transaction dates: Grant/award 2026-01-29; conversions reported 2026-05-04. Filing date: 2026-05-04 (filed well after the 2-business-day standard).
• Prices/values: All listed as $0.00 (derivative issuances/conversions; no cash paid or received per the report).
• Shares after transaction: Not specified in the provided filing excerpt.
• Footnotes:
  • F1: The 107,338-share instrument is a warrant granted 1/29/2026; underlying shares vest monthly in equal installments over three years (1/1/2026–1/1/2029).
  • F2: Series B and Series C preferred each converted into 22 common shares upon the IPO without further consideration; those preferred shares had no expiration.
• Timeliness: The Form 4 was filed on 2026-05-04 for a primary transaction dated 2026-01-29, i.e., later than the usual 2-business-day SEC filing window.

Context

• These were derivative transactions (a warrant grant and conversions of preferred/warrants into common stock), not open-market purchases or sales. Derivative conversions and awards often reflect internal restructurings, vesting schedules or IPO-related conversions rather than a director buying or selling stock in the market.
• Because the filing was late, the market received delayed disclosure of these insider actions; late filings do not change the reported transactions but reduce timeliness of investor information.